Total Payments
$501,881
2024 Payments
$70,036
Companies
43
Transactions
1,839
Medicare Patients
2,662
Medicare Billing
$1.1M
Payment Breakdown by Category
Other$352,210 (70.2%)
Consulting$61,832 (12.3%)
Travel$50,035 (10.0%)
Food & Beverage$37,342 (7.4%)
Education$461.89 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $345,335 | 179 | 68.8% |
| Consulting Fee | $61,832 | 22 | 12.3% |
| Travel and Lodging | $50,035 | 130 | 10.0% |
| Food and Beverage | $37,342 | 1,493 | 7.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,875 | 2 | 1.4% |
| Education | $461.89 | 13 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $112,179 | 282 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $93,676 | 195 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $80,360 | 138 | $0 (2024) |
| Axsome Therapeutics, Inc. | $73,805 | 71 | $0 (2024) |
| Allergan, Inc. | $55,710 | 151 | $0 (2020) |
| ABBVIE INC. | $42,174 | 122 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $21,868 | 123 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $5,685 | 26 | $0 (2022) |
| Neuronetics, Inc. | $2,797 | 39 | $0 (2022) |
| Neurocrine Biosciences, Inc. | $1,418 | 66 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $70,036 | 221 | Axsome Therapeutics, Inc. ($27,348) |
| 2023 | $107,742 | 254 | Axsome Therapeutics, Inc. ($46,457) |
| 2022 | $49,760 | 221 | Janssen Pharmaceuticals, Inc ($20,167) |
| 2021 | $11,884 | 109 | Otsuka America Pharmaceutical, Inc. ($5,427) |
| 2020 | $16,166 | 104 | Allergan, Inc. ($6,286) |
| 2019 | $60,899 | 285 | Janssen Pharmaceuticals, Inc ($23,124) |
| 2018 | $79,139 | 318 | Sunovion Pharmaceuticals Inc. ($34,966) |
| 2017 | $106,254 | 327 | Sunovion Pharmaceuticals Inc. ($55,795) |
All Payment Transactions
1,839 individual payment records from CMS Open Payments — Page 1 of 74
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $38.68 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/23/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $26.76 | General |
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $240.00 | General |
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $125.96 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $28.07 | General |
| Category: Neuropsychiatry | ||||||
| 12/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $10.35 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/17/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $4.23 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $32.48 | General |
| Category: Neuropsychiatry | ||||||
| 12/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $2.59 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $3.32 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $29.91 | General |
| Category: NEUROSCIENCE | ||||||
| 12/09/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $30.70 | General |
| Category: Neuroscience | ||||||
| 12/09/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $23.38 | General |
| 12/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/03/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: PSYCHIATRY | ||||||
| 12/01/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 11/26/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $25.04 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/26/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $19.75 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/26/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $0.57 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/21/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $15.72 | General |
| 11/20/2024 | Bausch Health US, LLC | WELLBUTRIN (Drug), APLENZIN | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Neurology | ||||||
| 11/20/2024 | Tris Pharma Inc | — | Food and Beverage | In-kind items and services | $15.73 | General |
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $5.93 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $1.76 | General |
| Category: Psychiatry/Psychology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 736 | 2,419 | $762,306 | $259,227 |
| 2022 | 10 | 741 | 2,803 | $981,630 | $330,252 |
| 2021 | 8 | 547 | 2,033 | $749,313 | $275,116 |
| 2020 | 8 | 638 | 2,228 | $774,479 | $264,847 |
Total Patients
2,662
Total Services
9,483
Medicare Billing
$1.1M
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2023 | 29 | 767 | $383,500 | $132,777 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 213 | 698 | $174,500 | $54,377 | 31.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 208 | 416 | $62,806 | $20,724 | 33.0% |
| 96130 | Evaluation of psychological test, first hour | Office | 2023 | 63 | 163 | $32,600 | $15,986 | 49.0% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 106 | 251 | $45,180 | $12,540 | 27.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 60 | 60 | $33,000 | $8,736 | 26.5% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2023 | 25 | 25 | $15,000 | $7,113 | 47.4% |
| 90869 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent motor threshold redetermination with delivery and management | Office | 2023 | 18 | 18 | $9,000 | $4,506 | 50.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 21 | $6,720 | $2,469 | 36.7% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2022 | 38 | 1,224 | $612,000 | $213,079 | 34.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 223 | 654 | $163,500 | $53,099 | 32.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 192 | 341 | $61,380 | $17,148 | 27.9% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 85 | 190 | $34,200 | $10,160 | 29.7% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2022 | 32 | 32 | $19,200 | $9,402 | 49.0% |
| 96136 | Administration of psychological or neuropsychological test, first 30 minutes | Office | 2022 | 61 | 227 | $34,050 | $8,479 | 24.9% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 61 | 61 | $33,550 | $8,057 | 24.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 30 | $9,600 | $4,186 | 43.6% |
| 90869 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent motor threshold redetermination with delivery and management | Office | 2022 | 15 | 15 | $7,500 | $3,768 | 50.2% |
| 96130 | Evaluation of psychological test, first hour | Office | 2022 | 19 | 29 | $6,650 | $2,874 | 43.2% |
| 90868 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), subsequent delivery and management, per session | Office | 2021 | 33 | 977 | $488,500 | $172,935 | 35.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 158 | 407 | $101,733 | $43,123 | 42.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 175 | 434 | $78,120 | $30,390 | 38.9% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 83 | 83 | $43,100 | $12,577 | 29.2% |
| 90867 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), initial delivery and management | Office | 2021 | 33 | 33 | $19,800 | $9,822 | 49.6% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 33 | 52 | $9,360 | $3,068 | 32.8% |
About Dr. Tarique Perera, M.D
Dr. Tarique Perera, M.D is a Psychiatry healthcare provider based in Danbury, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730195751.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tarique Perera, M.D has received a total of $501,881 in payments from pharmaceutical and medical device companies, with $70,036 received in 2024. These payments were reported across 1,839 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($345,335).
As a Medicare-enrolled provider, Perera has provided services to 2,662 Medicare beneficiaries, totaling 9,483 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Danbury, CT
- Active Since 07/31/2006
- Last Updated 08/08/2013
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1730195751
Products in Payments
- REXULTI (Drug) $111,740
- VRAYLAR (Drug) $97,849
- LATUDA (Drug) $93,676
- SPRAVATO (Drug) $80,203
- Auvelity (Drug) $39,681
- Sunosi (Drug) $34,124
- Trintellix (Drug) $21,160
- SUNOSI (Drug) $5,649
- NEUROSTAR TMS THERAPY (Device) $1,505
- INGREZZA (Drug) $1,378
- ABILIFY MAINTENA (Drug) $1,196
- NeuroStar TMS Therapy (Device) $1,193
- TRINTELLIX (Drug) $1,036
- CAPLYTA (Drug) $925.58
- Qelbree (Drug) $681.34
- ARISTADA (Drug) $619.70
- WELLBUTRIN (Drug) $591.14
- VYVANSE (Drug) $518.33
- Horizant (Drug) $490.66
- Azstarys (Drug) $401.93
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Danbury
Dr. Donald Ammerman, M.d, M.D
Psychiatry — Payments: $1.2M
Psychiatry $1.2M
Dr. Ghazi Asaad, M.d, M.D
Psychiatry — Payments: $29,073
Psychiatry $29,073
Joseph Williams, M.d, M.D
Psychiatry — Payments: $26,965
Psychiatry $26,965
Dr. Jeffrey Satinover, M.d., Ph.d, M.D., PH.D
Psychiatry — Payments: $19,346
Psychiatry $19,346
Dr. Mark Ligorski, Md, MD
Psychiatry — Payments: $7,858
Psychiatry $7,858
Kristen Sadana, M.d, M.D
Psychiatry — Payments: $5,053
Psychiatry $5,053